A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

This study tests a drug called AK112 — which blocks two proteins (PD-1 and VEGF) that allow cancer to hide from the immune system and grow new blood vessels — as an after-surgery (adjuvant) treatment for liver cancer (hepatocellular carcinoma, or HCC) with high risk of recurrence. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with liver cancer (HCC) and had it surgically removed - Your cancer had at least one high-risk feature suggesting it might come back (e.g., large tumor, vascular invasion, multiple nodules) - You have adequate liver, kidney, and blood function - You did not receive any other cancer treatment before surgery **You may NOT be eligible if...** - Your cancer had spread to lymph nodes or other organs before surgery - You received chemotherapy, immunotherapy, or other cancer treatment before your surgery - You have Child-Pugh Class C liver disease (severe liver failure) - You have autoimmune disease or certain active infections Talk to your doctor to see if this trial is right for you.